Polyuria and weight-loss associated with cimetidine

Sir,

Acute interstitial nephritis (AIN) is a recognized side effect of numerous drugs, including cimetidine, and is frequently non-oliguric. There is only one previously published report of cimetidine-associated AIN featuring polyuria and weight-loss.

An otherwise healthy 52 year old male was found to have a duodenal ulcer. After 10 weeks of treatment with cimetidine, at standard dosage, he was admitted with a 3 week history of weight loss of 5 kg, polyuria and polydipsia. Other symptoms included profuse nocturnal sweating, anorexia, headache and profound malaise. Abnormal findings on examination were a pyrexia of 38°C, pallor and tenderness on deep palpation of the flanks. There was no rash, lymphadenopathy or evidence of arthritis, and he was normotensive.

On investigation, he was found to be anaemic (haemoglobin 11.8 g/dl), with an eosinophilia (648 x 10⁶/l) and a raised ESR (80 mm/first hour). Urea was 11.8 mmol/l, creatinine 0.290 mmol/l, sodium 141 mmol/l and potassium 3.7 mmol/l. He was hypocalcaemic (2.09 mmol/l), with normal levels of albumin, phosphate and glucose. Daily urine outputs were between 4 and 6 litres, creatinine clearance was 54 ml/min and 24 hour urinary protein 400 mg. Radiology of the renal tract and repeated urine microscopy and culture were normal. During a water-deprivation test, the plasma osmolality rose from 285 to 305 mosmol/kg, whilst the urine output remained relatively high (> 70 ml/hour) and hypo-osmolar (<290 mosmol/kg).

A diagnosis of impaired urine concentrating ability, probably due to AIN, was made, and the cimetidine was stopped. Within 3 days, the fever and other symptoms, apart from polyuria, had disappeared. Over the next 3 months, complete recovery ensued.

On the basis of at least 17 published reports, the manufacturers of cimetidine acknowledge AIN as a 'very rare complication, reversible on withdrawal of the drug'. In this case, a clinical diagnosis of drug-induced AIN was made on the basis of an episode of acute renal failure, associated with fever, eosinophilia, renal tenderness and evidence of tubulo-interstitial dysfunction, with rapid recovery upon withdrawal of the drug.

By interfering with the production of the medullary osmotic gradient, AIN is likely to result in a degree of impairment of urinary-concentrating ability. Reports of drug-associated AIN, featuring clinically manifest impaired urinary concentrating ability are, however, very rare. Cimetidine-induced AIN has only once previously been reported in association with polyuria.2

In conclusion, weight loss, subsequent upon polyuria, may be a presenting symptom of drug-induced AIN. This may be acute, as in my patient, or more chronic, with symptomatic polyuria only being manifest after some months of weight loss. Such weight loss could be mistakenly ascribed to the illness for which the offending drug is prescribed.

P.J. Mullen
Medical Division,
Royal Air Force Hospital,
Halton, Aylesbury,
Bucks HP22 5PG, UK.

References

Amiodarone and hair loss

Sir,

We would like to report a case of hair loss and photosensitive rash associated with the use of amiodarone. A 61 year old woman with hypertrophic cardiomyopathy was started on amiodarone for paroxysmal ventricular tachycardia. She tolerated this well and had no problems until the development of a photosensitive skin rash 7 months later, during the summer, followed by marked hair loss from her scalp. Daily medication at this time was diltiazem 60 mg, bendrofluazide 5 mg, aspirin 150 mg, diazepam 2 mg, and amiodarone 200 mg. Therapy with amiodarone was stopped and the rash disappeared within 2 months. Hair loss only ceased about 3 months after discontinuation of amiodarone treatment, and there has been subsequent regrowth of scalp hair.

Amiodarone is well known for the variety of side effects associated with its use, but hair loss has only been reported previously in three patients.2,3 In our patient the temporal relationship between amiodarone treatment and the development and subsidence of both skin rash and hair loss suggest amiodarone as the causal agent. There were no other changes in medication over this period and no clinical evidence of thyroid dysfunction. Hair loss, though not life threatening, provokes great anxiety and social embarrassment in patients, and therefore deserves attention.

L.M. Samuel
M. Davie
I.R. Starkey
Departments of Cardiology and Pharmacy,
Western General Hospital,
Crewe Road,
Edinburgh EH4 2XJ, UK.

References
Amiodarone and hair loss.

L. M. Samuel, M. Davie and I. R. Starkey

doi: 10.1136/pgmj.68.803.771-a

Updated information and services can be found at:
http://pmj.bmj.com/content/68/803/771.2.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/